DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2026)

Migraine | Landscape & Forecast | Disease Landscape & Forecast

Migraine | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The migraine therapy market comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. We anticipate the launch of several new brands, including novel triptan and DHE reformulations and promising nontriptan alternatives. Among them are Eli Lilly’s 5-HT1F receptor agonist lasmiditan and two oral calcitonin gene-related peptide (CGRP) receptor antagonists—Allergan’s ubrogepant and Biohaven’s rimegepant. They will support future growth in the large acute segment. However, it is the 2018 launch of three premium-priced anti-CGRP MAbs (a fourth is expected in 2020) for migraine prophylaxis in both episodic and chronic migraineurs that will be the main driver of multibillion-dollar sales growth of this market. These drugs follow in the footsteps of Allergan’s Botox (approved for chronic migraine), which has proven the commercial opportunity that new, valued brand alternatives can seize in the otherwise generic prophylaxis segment.

Questions Answered:

  • How will Amgen / Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Alder’s eptinezumab compete with one another and with established prophylactic therapies as their marketers vie for patient share? How will the launch of two oral CGRP antagonists impact the migraine prophylaxis market?
  • Will novel NMEs lasmiditan, ubrogepant, and rimegepant gain a foothold in the heavily generic acute segment dominated by triptans?
  • How will novel triptan and DHE reformulations, including Zosano’s Qtrypta and Impel NeuroPharma’s INP-104, compete for patient share with existing branded and generic non-oral options in the small niche patient population in need of non-oral alternatives?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • April 2019
      • November 2018
      • September 2018
      • August 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Migraine?
        • What Factors Are Constraining the Market for Migraine?
      • Segment-Specific Trends
        • Acute Treatment of Migraine
        • Migraine Prophylaxis
        • Episodic and Chronic Migraine
      • Drug-Class-Specific Trends
        • 5-HT1B/1D Receptor Agonists
        • Ergot Derivatives
        • 5-HT1F Receptor Agonists
        • Other Acute Therapies
        • Anti-CGRP Monoclonal Antibodies
        • CGRP Receptor Antagonists
        • Other Prophylactic Therapies
      • Alternative Market Scenarios
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Genetic Factors
      • Environmental Factors: Migraine Triggers
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Migraine Prevalence
        • Episodic Migraine Prevalence
        • Chronic Migraine Prevalence
        • Frequency of Episodic Migraine Attacks
        • Total Episodic Migraine Events
        • Diagnosed Prevalent Cases of Migraine
        • Drug-Treated Cases of Migraine
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies: Acute Treatment
        • Overview
        • 5-HT1 Receptor Agonists
        • Dihydroergotamine Mesylate
        • Prescription NSAIDs and Non-Narcotic Analgesics
        • Narcotic Prescription Analgesics
      • Key Current Therapies: Prophylactic Treatment
        • Overview
        • Antiepileptic Drugs
        • Neuromuscular Blocking Agents
        • Anti-CGRP Monoclonal Antibodies
        • Beta Blockers
        • Antidepressants
        • Calcium-Channel Blockers
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Migraine
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Migraine
        • Triptan Reformulations
        • Ergot Derivatives
        • 5-HT1F Receptor Agonists
        • COX-2 Inhibitors
        • Anti-CGRP Monoclonal Antibodies
        • CGRP Receptor Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Migraine
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Migraine Bibliography

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Angela Sparrow, PhD; Shilpa Thakur
  • Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain. Dr. Sparrow holds a in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.

  • Shilpa Thakur is a medical graduate with a from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio. Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.  

Purchase Report

Recent reports:
You may also be interested in: